Trevi Therapeutics Inc

Trevi Therapeutics (NASDAQ: TREV) shows volatile stock but focuses on two clinical‑stage drugs for cough and dyskinesia; investors should weigh pipeline milestones over market noise.

Trevi Therapeutics Inc is a pharmaceutical company navigating high-risk, high-reward innovation in the health care sector, with its stock price and financial health reflecting the challenges and uncertainties of the industry.

Trevi Therapeutics, a pharmaceutical company, is advancing treatments for chronic cough and dyskinesia, positioning itself as a key player in the healthcare sector with a market capitalization of $919.58 million.

Trevi Therapeutics, a pharmaceutical company, is set to release its Q1 2025 financial results on May 8, 2025, with investors closely watching for updates on its financial performance and pipeline of treatments.